{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:50:19Z","timestamp":1794012619501,"version":"4.8.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001691","name":"KAKENHI","doi-asserted-by":"publisher","award":["23K19497"],"award-info":[{"award-number":["23K19497"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"KAKENHI","doi-asserted-by":"publisher","award":["24K19665"],"award-info":[{"award-number":["24K19665"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008673","name":"Yasuda Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007428","name":"Naito Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study investigated clinical benefits of androgen receptor signaling inhibitor (ARSI) in patients with synchronous metastatic hormone-sensitive prostate cancer (mHSPC) based on real-world data from multiple centers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical records of 1107 mHSPC patients who commenced vintage (bicalutamide) (n\u00a0=\u00a0801) or ARSI (n\u00a0=\u00a0306) treatment in addition to androgen deprivation therapy between 1999 and 2024 were reviewed. Progression-free and overall survival (OS) were examined, and prognostic factors were analyzed using multivariate cox proportional hazard modeling. Propensity score matching (PSM) analysis was performed to balance background characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median age and initial prostate-specific antigen level were 73\u00a0years and 229\u00a0ng\/ml, respectively. Kaplan\u2013Meier analysis revealed that upfront ARSI treatment was associated with longer progression-free survival (P\u00a0&amp;lt;\u00a00.0001, hazard ratio [HR]\u00a0=\u00a00.37) and OS (P\u00a0=\u00a00.0088, HR\u00a0=\u00a00.58) than combined androgen blockade after PSM analysis. In particular, an OS benefit of upfront ARSI was observed in high-volume patients (P\u00a0=\u00a00.0052, HR\u00a0=\u00a00.56). ARSI use after castration-resistant prostate cancer (CRPC) development correlated with improved OS as compared to patients without ARSI use (P\u00a0&amp;lt;\u00a00.0001, HR\u00a0=\u00a00.52). Multivariate analysis identified ARSI therapy as an independent prognostic factor for OS both when used upfront (P\u00a0=\u00a00.0141, HR\u00a0=\u00a00.61) and after CRPC development (P\u00a0&amp;lt;\u00a00.0001, HR\u00a0=\u00a00.55). In addition, categorizing all patients into groups receiving no ARSI, ARSI after CRPC, or ARSI as upfront therapy revealed 5-year OS rates of 55.65%, 59.85%, and 65.01%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Early use of ARSI in Japanese patients with mHSPC appears clinically beneficial. Our findings suggest the prognostic importance for optimal treatment intensification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyaf079","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T23:42:28Z","timestamp":1747525348000},"page":"954-962","source":"Crossref","is-referenced-by-count":6,"title":["Clinical benefits of androgen receptor signaling inhibitors in patients with metastatic hormone-sensitive prostate cancer: real-world data from a multi-center study"],"prefix":"10.1093","volume":"55","author":[{"given":"Yosuke","family":"Kinoshita","sequence":"first","affiliation":[{"name":"Department of Urology, Chiba University Graduate School of Medicine , 1.8.1, Inohana, Chuo.ku, Chiba.City, Chiba 2608670 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Urology, Chiba University Graduate School of Medicine , 1.8.1, Inohana, Chuo.ku, Chiba.City, Chiba 2608670 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Tsujino","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka Medical and Pharmaceutical University , 2-7 Daigaku-Machi, Takatsuki-City, Osaka 5698686 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Urology, Chiba University Graduate School of Medicine , 1.8.1, Inohana, Chuo.ku, Chiba.City, Chiba 2608670 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kodai","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Urology, Chiba University Graduate School of Medicine , 1.8.1, Inohana, Chuo.ku, Chiba.City, Chiba 2608670 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinpei","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Urology, Chiba University Graduate School of Medicine , 1.8.1, Inohana, Chuo.ku, Chiba.City, Chiba 2608670 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka Medical and Pharmaceutical University , 2-7 Daigaku-Machi, Takatsuki-City, Osaka 5698686 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka Medical and Pharmaceutical University , 2-7 Daigaku-Machi, Takatsuki-City, Osaka 5698686 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka Medical and Pharmaceutical University , 2-7 Daigaku-Machi, Takatsuki-City, Osaka 5698686 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Kimitsu Chuo Hospital , 1010, Sakurai, Kisarazu-City, Chiba 2928535 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Urology, Chiba Rosai Hospital , 2-16, Tatsumidaihigashi, Ichihara-City, Chiba 2900003 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Urology, Chibaken Saiseikai Narashino Hospital , 1-1-1, Izumi, Narashino-City, Chiba 2758580 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Department of Urology, Funabashi Municipal Hospital , 1-21-1, Kanasugi, Funabashi-City, Chiba 2738588 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Takei","sequence":"additional","affiliation":[{"name":"Department of Urology, Matsudo City General Hospital , 993-1, Sendabori, Matsudo-City, Chiba 2702296 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manato","family":"Kanesaka","sequence":"additional","affiliation":[{"name":"Department of Urology, Chiba University Graduate School of Medicine , 1.8.1, Inohana, Chuo.ku, Chiba.City, Chiba 2608670 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Urology, Chiba University Graduate School of Medicine , 1.8.1, Inohana, Chuo.ku, Chiba.City, Chiba 2608670 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangjon","family":"Pae","sequence":"additional","affiliation":[{"name":"Department of Urology, Chiba University Graduate School of Medicine , 1.8.1, Inohana, Chuo.ku, Chiba.City, Chiba 2608670 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanji","family":"Kanaoka","sequence":"additional","affiliation":[{"name":"Department of Urology, Kimitsu Chuo Hospital , 1010, Sakurai, Kisarazu-City, Chiba 2928535 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobushige","family":"Takeshita","sequence":"additional","affiliation":[{"name":"Department of Urology, Fukaya Red Cross Hospital , 5-8-1, Kamishibacho-nishi, Fukaya-City, Saitama 3660052 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Yoneda","sequence":"additional","affiliation":[{"name":"Prostate Center and Division of Urology, Chiba Cancer Center , 666-2, Nitona-cho, Chiba-City, Chiba 2608717 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Hino","sequence":"additional","affiliation":[{"name":"Department of Urology, Asahi General Hospital , 1326, Asahi-City, Chiba 2892511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokazu","family":"Sazuka","sequence":"additional","affiliation":[{"name":"Department of Urology, Chiba University Graduate School of Medicine , 1.8.1, Inohana, Chuo.ku, Chiba.City, Chiba 2608670 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Imamura","sequence":"additional","affiliation":[{"name":"Department of Urology, Chiba University Graduate School of Medicine , 1.8.1, Inohana, Chuo.ku, Chiba.City, Chiba 2608670 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Mikami","sequence":"additional","affiliation":[{"name":"Department of Urology, Chibaken Saiseikai Narashino Hospital , 1-1-1, Izumi, Narashino-City, Chiba 2758580 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Urology, Kimitsu Chuo Hospital , 1010, Sakurai, Kisarazu-City, Chiba 2928535 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Fukasawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Funabashi Municipal Hospital , 1-21-1, Kanasugi, Funabashi-City, Chiba 2738588 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kurozumi","sequence":"additional","affiliation":[{"name":"Department of Urology, Fukaya Red Cross Hospital , 5-8-1, Kamishibacho-nishi, Fukaya-City, Saitama 3660052 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Naya","sequence":"additional","affiliation":[{"name":"Department of Urology, Teikyo University Chiba Medical Center , 3426-3, Anesaki, Ichihara-City, Chiba 2990111 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of Urology, Yokohama Rosai Hospital , 3211, Kodukue, Yokohama-City, Kanagawa 2220036 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Komaru","sequence":"additional","affiliation":[{"name":"Prostate Center and Division of Urology, Chiba Cancer Center , 666-2, Nitona-cho, Chiba-City, Chiba 2608717 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyofusa","family":"Tobe","sequence":"additional","affiliation":[{"name":"Department of Urology, Saiseikai Utsunomiya Hospital , 911-1, Takebayashi-cho, Utsunomiya-City, Tochigi 3210974 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Urology, Asahi General Hospital , 1326, Asahi-City, Chiba 2892511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhito","family":"Azuma","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka Medical and Pharmaceutical University , 2-7 Daigaku-Machi, Takatsuki-City, Osaka 5698686 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Chiba University Graduate School of Medicine , 1.8.1, Inohana, Chuo.ku, Chiba.City, Chiba 2608670 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Chiba University Graduate School of Medicine , 1.8.1, Inohana, Chuo.ku, Chiba.City, Chiba 2608670 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,18]]},"reference":[{"key":"2025080402265419300_ref1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025080402265419300_ref2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.canlet.2021.06.010","article-title":"The treatment landscape of metastatic prostate cancer","volume":"519","author":"Yamada","year":"2021","journal-title":"Cancer Lett"},{"key":"2025080402265419300_ref3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"2025080402265419300_ref4","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"2025080402265419300_ref5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"2025080402265419300_ref6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"2025080402265419300_ref7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"2025080402265419300_ref8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"2025080402265419300_ref9","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi","year":"2020","journal-title":"N Engl J Med"},{"key":"2025080402265419300_ref10","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"2025080402265419300_ref11"},{"key":"2025080402265419300_ref12","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/j.1464-410X.2006.06201.x","article-title":"Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men","volume":"97","author":"Fukagai","year":"2006","journal-title":"BJU Int"},{"key":"2025080402265419300_ref13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1177\/107327480901600210","article-title":"Impact of androgen deprivation therapy on racial\/ethnic disparities in the survival of older men treated for locoregional prostate cancer","volume":"16","author":"Holmes","year":"2009","journal-title":"Cancer Control"},{"key":"2025080402265419300_ref14","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/iju.13372","article-title":"Therapies for castration-resistant prostate cancer in a new era: the indication of vintage hormonal therapy, chemotherapy and the new medicines","volume":"24","author":"Mizokami","year":"2017","journal-title":"Int J Urol"},{"key":"2025080402265419300_ref15","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/iju.15498","article-title":"Prognostic outcomes in Japanese patients with metastatic castration-sensitive prostate cancer: comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor","volume":"31","author":"Watanabe","year":"2024","journal-title":"Int J Urol"},{"key":"2025080402265419300_ref16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10147-024-02670-5","article-title":"Efficacy of androgen receptor signaling inhibitors in combination with androgen deprivation therapy for castration-sensitive metastatic prostate cancer: a retrospective analysis in a Japanese cohort","volume":"30","author":"Taga","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"2025080402265419300_ref17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"2025080402265419300_ref18","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025080402265419300_ref19","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025080402265419300_ref20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.35772\/ghm.2024.01019","article-title":"Comparison of oncological outcomes of upfront androgen receptor signaling inhibitors and combined androgen blockade in Japanese patients with metastatic castration-sensitive prostate cancer","volume":"6","author":"Noda","year":"2024","journal-title":"Global Health Med"},{"key":"2025080402265419300_ref21","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s00345-022-03963-y","article-title":"Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy","volume":"40","author":"Narita","year":"2022","journal-title":"World J Urol"},{"key":"2025080402265419300_ref22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.euo.2023.12.013","article-title":"Clinical outcomes of patients with high-risk metastatic hormone-na\u00efve prostate cancer: a 3-year interim analysis of the observational J-ROCK study","volume":"7","author":"Miyake","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"2025080402265419300_ref23","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/iju.14993","article-title":"Treatment strategies and outcomes in a long-term registry study of patients with high-risk metastatic hormone-na\u00efve prostate cancer in Japan: an interim analysis of the J-ROCK study","volume":"29","author":"Uemura","year":"2022","journal-title":"Int J Urol"},{"key":"2025080402265419300_ref24","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.21873\/anticanres.16283","article-title":"Is it necessary to treat all metastatic prostate cancer with upfront androgen receptor axis-targeted agents?","volume":"43","author":"Nakagawa","year":"2023","journal-title":"Anticancer Res"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/8\/954\/63217557\/hyaf079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/8\/954\/63217557\/hyaf079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T06:27:00Z","timestamp":1754288820000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/8\/954\/8134309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,18]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,5,18]]},"published-print":{"date-parts":[[2025,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf079","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,5,18]]}}}